Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-6

FDA-Pt () and markers for ATP7A and ATP7B (both ) in A2780 and A2780cis cells. , the structure is positive for CFDA-Pt and protein markers. Ovals indicate cell periphery. Scale bar, 10 μm.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-5

Labelled with LysoTracker™ Red (), cell nuclei were stained with Hoechst 33342 (). Ovals indicate cell periphery. Scale bar, 5 μm. B. The results represent means ± SE of four experiments. The significance of differences was analysed using Student's test.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-2

Ells in the drug-free medium for 1 h. Cell nuclei were stained with propidium iodide (). Ovals indicate cell periphery. Scale bar, 10 μm.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-1

Or Golgi and protein markers. Ovals indicate cell periphery. Scale bar, 10 μm.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-4

Itation wavelengths (485 nm and 460 nm) after FITC-dextran labelling of endosomes and lysosomes, respectively. The results are expressed as means ± SE of emission intensity ratios in 24 wells (endosomes) and 48 wells (lysosomes) from two independent experiments. The significance of differences was analysed using Student's test.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-7

Als indicate cell periphery. Scale bar, 10 μm.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-3

With propidium iodide (). Ovals indicate cell periphery. Scale bar, 10 μm.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-9

Ells in the drug-free medium for 1 h. Cell nuclei were stained with propidium iodide (). Ovals indicate cell periphery. Scale bar, 10 μm.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-0

Als indicate cell periphery. Scale bar, 10 μm.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells-8

Or Golgi and protein markers. Ovals indicate cell periphery. Scale bar, 10 μm.<p><b>Copyright information:</b></p><p>Taken from "Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells"</p><p>http://www.biomedcentral.com/1471-2407/8/175</p><p>BMC Cancer 2008;8():175-175.</p><p>Published online 19 Jun 2008</p><p>PMCID:PMC2442842.</p><p></p